1. Home
  2. PASG

as 02-21-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.

Founded: 2017 Country:
United States
United States
Employees: N/A City: PHILADELPHIA
Market Cap: 42.2M IPO Year: 2020
Target Price: $8.00 AVG Volume (30 days): 136.2K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.17 EPS Growth: N/A
52 Week Low/High: $0.45 - $1.79 Next Earning Date: 03-03-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

PASG Daily Stock ML Predictions

Stock Insider Trading Activity of Passage Bio Inc. (PASG)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Borthwick Kathleen PASG CFO Feb 10 '25 Sell $0.53 3,183 $1,685.72 41,283
ORBIMED ADVISORS LLC PASG 10% Owner Jan 10 '25 Sell $0.63 223,219 $142,223.38 7,131,636
ORBIMED ADVISORS LLC PASG 10% Owner Jan 6 '25 Sell $0.72 147,024 $103,305.69 7,131,636
Lynx1 Capital Management LP PASG 10% Owner Dec 27 '24 Buy $0.65 373,645 $241,038.39 9,256,953
ORBIMED ADVISORS LLC PASG 10% Owner Dec 20 '24 Sell $0.60 230,321 $138,192.60 7,131,636
ORBIMED ADVISORS LLC PASG 10% Owner Dec 9 '24 Sell $0.81 62,276 $51,988.04 7,131,636
ORBIMED ADVISORS LLC PASG 10% Owner Dec 4 '24 Sell $0.80 97,103 $77,338.46 7,131,636
Lynx1 Capital Management LP PASG 10% Owner Nov 25 '24 Buy $0.65 456,353 $284,519.51 9,256,953

Share on Social Networks: